Developing best-in-class therapies that can improve the health of patients with liver and gastrointestinal (GI) diseases
NASH is expected to become the leading cause for liver transplants in the United States.
Inflammatory bowel disease is increasing in prevalence worldwide
Metacrine is building a pipeline of potential best-in-class FXR agonist therapeuties for NASH and other GI diseases